EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieStudienprotokollOpen Access · CC BY-NC 4.0

The Dedicated Imaging Post‐Prostatectomy for Enhanced Radiotherapy outcomes ( DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low‐risk biochemical recurrence after radical prostatectomy

Matthew J Roberts iD, Ciara Conduit iD, Ian D Davis iD, Rachel M Effeney, Scott Williams iD, Jarad M Martin iD, Michael S Hofman iD, George Hruby, Renu Eapen, Chris Gianacas iD, Nathan Papa iD, Richard De Abreu Lourenço iD und 6 weitere

BJU International · 2024

DOI: 10.1111/bju.16158 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift BJU International, 2024. Verfasst von Matthew J Roberts und 17 weiteren Autor:innen. Beteiligte Einrichtung: The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Camperdown, NSW, Australia. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Prostatic Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Mundipharma International.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background Salvage radiation therapy (SRT) and surveillance for low‐risk prostate‐specific antigen (PSA) recurrence have competing risks and benefits. The efficacy of early SRT to the prostate bed with or without pelvic lymph nodes compared to surveillance in patients with PSA recurrence after radical prostatectomy and no identifiable recurrent disease evident on prostate specific membrane antigen‐positron emission tomography/computer tomography (PSMA‐PET/CT) is unknown. Study Design The Dedicated Imaging Post‐Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) is an open‐label, multicentre, randomised Phase II trial. Endpoints The primary endpoint is 3‐year event‐free survival, with events comprising one of PSA recurrence (PSA ≥0.2 ng/mL higher than baseline), radiological evidence of metastatic disease, or initiation of systemic or other salvage treatments. Secondary endpoints include patient‐reported outcomes, treatment patterns, participant perceptions, and cost‐effectiveness. Eligibility Criteria Eligible participants have PSA recurrence of prostate cancer after radical prostatectomy, defined by serum PSA level of 0.2–0.5 ng/mL, deemed low risk according to modified European Association of Urology biochemical recurrence risk criteria (International Society for Urological Pathology Grade Group ≤2, PSA doubling time >12 months), with no definite/probable recurrent prostate cancer on PSMA‐PET/CT. Patients and Methods A total of 100 participants will be recruited from five Australian centres and randomised 1:1 to SRT or surveillance. Participants will undergo 6‐monthly clinical evaluation for up to 36 months. Androgen‐deprivation therapy is not permissible. Enrolment commenced May 2023. Trial Registration This trial has been registered with the Australian New Zealand Clinical Trials Registry (ACTRN: ACTRN12622001478707).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostate-Specific AntigenProstatic NeoplasmsMaleHumansProstatePositron Emission Tomography Computed TomographyAndrogen AntagonistsNeoplasm Recurrence, LocalAustraliaProstatectomySalvage TherapyGallium RadioisotopesRandomized Controlled Trials as TopicMulticenter Studies as TopicClinical Trials, Phase II as Topic

Stichwörter der Autor:innen

clinical trial protocolpatient-reported outcome measurespositron emission tomography-computed tomographyprostate neoplasmprostate-specific antigenradical prostatectomyradiotherapy

Substanzen

Prostate-Specific AntigenAndrogen AntagonistsGallium Radioisotopes

Autor:innen und Institutionen

  • The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Camperdown, NSW, Australia.
  • Royal Brisbane and Women's Hospital, Herston, Qld, Australia.
  • Redcliffe Hospital, Redcliffe, Qld, Australia.
  • Faculty of Medicine, Centre for Clinical Research, The University of Queensland, Brisbane, Qld, Australia.
  • Walter and Eliza Hall Institute of Medical Research, Melbourne, Vic., Australia.
  • Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Vic., Australia.

ORCID-Profile: Matthew J Roberts, Ciara Conduit, Ian D Davis, Scott Williams, Jarad M Martin, Michael S Hofman, Chris Gianacas, Nathan Papa, Richard De Abreu Lourenço, Haryana M Dhillon, Louise Emmett

Förderung

  • Australian and New Zealand Urogenital and Prostate Cancer Trials Group
  • Mundipharma International

Zitieren

APA

Roberts, M. J., Conduit, C., Davis, I. D., Effeney, R. M., Williams, S., Martin, J. M., Hofman, M. S., Hruby, G., Eapen, R., Gianacas, C., Papa, N., Lourenço, R. A., Dhillon, H. M., Allen, R., Fontela, A., Kaur, B., Emmett, L., & Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2024). The Dedicated Imaging Post‐Prostatectomy for Enhanced Radiotherapy outcomes ( DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low‐risk biochemical recurrence after radical prostatectomy. BJU International. https://doi.org/10.1111/bju.16158

Vancouver

Roberts MJ, Conduit C, Davis ID, Effeney RM, Williams S, Martin JM, et al. The Dedicated Imaging Post‐Prostatectomy for Enhanced Radiotherapy outcomes ( DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low‐risk biochemical recurrence after radical prostatectomy. BJU International. 2024. doi:10.1111/bju.16158

BibTeX
@article{Roberts2024,
  author = {Roberts, Matthew J and Conduit, Ciara and Davis, Ian D and Effeney, Rachel M and Williams, Scott and Martin, Jarad M and Hofman, Michael S and Hruby, George and Eapen, Renu and Gianacas, Chris and Papa, Nathan and Lourenço, Richard De Abreu and Dhillon, Haryana M and Allen, Ray and Fontela, Antoinette and Kaur, Baldeep and Emmett, Louise and Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)},
  title = {The Dedicated Imaging Post‐Prostatectomy for Enhanced Radiotherapy outcomes ( DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low‐risk biochemical recurrence after radical prostatectomy},
  journal = {BJU International},
  year = {2024},
  doi = {10.1111/bju.16158}
}
Kostenlos starten →